Jeanette A. Stewart

Learn More
PURPOSE To validate the treatment-specific Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). METHODS Item content was developed by 4 heterogeneous patient focus groups (n = 32). Instrument validation involved 250 patients on ocular hypotensive medications recruited from ophthalmology practices in the Southern USA. Participants responded to(More)
PURPOSE To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension. DESIGN Prospective, multi-center, historical control study. METHODS Patients treated with latanoprost or bimatoprost who needed alternative therapy due to(More)
The capability of a pulsed Doppler flowmeter combined with a phased-array imaging system to measure volume flow was tested in vitro and in patients undergoing cardiac catheterization. The Doppler-phased-array system (DPA) was used to determine vessel diameter and a superimposed cursor was used to locate the range and angle of the Doppler sample volume. DPA(More)
PURPOSE To assess the safety and efficacy of changing to the travoprost/timolol fixed combination (TTFC) from other mono- or adjunctive therapies. PATIENTS AND METHODS A prospective, open-label, observational cohort of primary open-angle glaucoma and ocular hypertensive patients whose intraocular pressure (IOP) was uncontrolled on prior therapy or was not(More)
OBJECTIVE To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients living in the US who had primary open-angle glaucoma or ocular hypertension. METHODS This was an open-label, multicenter, bilateral, intraindividual, and active-controlled(More)
PURPOSE To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients. DESIGN Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes. METHODS At Visit 1, qualified patients began a glaucoma(More)
PURPOSE To evaluate progression rates with dorzolamide compared with other hypotensive agents in primary open-angle glaucoma. METHODS Patients who were treated over 5 years with dorzolamide versus other hypotensive agents were reviewed. The groups were matched by intraocular pressure, cardiovascular history, and age. RESULTS In 50 matched pairs, 2 (4%)(More)
Wilson's Disease (WD) (also known as hepatolenticular degeneration) is a rare inherited autosomal recessive disorder of abnormal copper metabolism, with an estimated prevalence of approximately 1 in 30,000. The clinical features associated with WD are highly varied. However, subtypes generally reflect neurological, hepatic, and psychiatric symptoms. The(More)
The purpose of this article is to review the prior research evaluating design techniques for glaucoma clinical trials to help ophthalmologists and pharmaceutical sponsors better develop literature-based studies that are cost- and time-efficient. We performed this study using known published articles by the authors and literature found on Pub Med. We(More)